RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City

RenovoRx CEO Shaun Bagai will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. The presentation will cover the company's commercialization efforts and Phase III TIGeR-PaC clinical trial developments for its oncology therapies. Bagai will also discuss RenovoRx's patented RenovoCath drug-delivery device and its organic revenue growth. The presentation will be available on the company's investor relations website.

RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, has announced that its CEO, Shaun Bagai, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025 [1]. The presentation will cover the company's ongoing commercialization efforts, organic revenue growth, and the latest developments in its Phase III TIGeR-PaC clinical trial.

Mr. Bagai will discuss RenovoRx’s ongoing commercialization efforts, highlighting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. He will also present updates on the company's Phase III TIGeR-PaC trial, which is evaluating RenovoRx’s novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of locally advanced pancreatic cancer (LAPC) [2].

The TIGeR-PaC trial is currently under investigation and has not been approved for commercial sale. However, it has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon new drug application approval by the FDA [3].

RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. The company has already received its first commercial purchase orders for RenovoCath devices and has initiated repeat orders from several high-volume National Cancer Institute-designated centers [4].

Mr. Bagai’s presentation will be available for the duration of the conference and afterwards on the Company's IR website. To schedule a one-on-one investor meeting with Mr. Bagai, please contact KCSA Strategic Communications at RenovoRx@KCSA.com.

References:
[1] https://www.nasdaq.com/press-release/renovorx-ceo-shaun-bagai-present-hc-wainwrights-27th-annual-global-investment
[2] https://www.nasdaq.com/press-release/renovorx-ceo-shaun-bagai-present-hc-wainwrights-27th-annual-global-investment
[3] https://www.nasdaq.com/press-release/renovorx-ceo-shaun-bagai-present-hc-wainwrights-27th-annual-global-investment
[4] https://www.nasdaq.com/press-release/renovorx-ceo-shaun-bagai-present-hc-wainwrights-27th-annual-global-investment